Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Pembrolizumab plus lenvatinib is an effective and tolerable treatment for mRCC also in the real-world setting.
Authors
- Maria Teresa Bourlon (ORCID: https://orcid.org/0000-0002-3116-912X)
- Tarek Taha (ORCID: https://orcid.org/0000-0001-7936-5245)
- Bohuslav Melichar (ORCID: https://orcid.org/0000-0002-5474-6866)
- Zin Myint (ORCID: https://orcid.org/0000-0002-3479-4203)
- Sebastiano Buti (ORCID: https://orcid.org/0000-0003-0876-0226)
- Camillo Porta (ORCID: https://orcid.org/0000-0003-2412-1563)
- Matteo Santoni (ORCID: https://orcid.org/0000-0001-7340-6173)
- Thomas Büttner (ORCID: https://orcid.org/0000-0003-0316-9621)
- Jakub Kucharz (ORCID: https://orcid.org/0000-0001-5388-8910)
- Andrey Soares (ORCID: https://orcid.org/0000-0003-4980-6729)
- Veronica Mollica (ORCID: https://orcid.org/0000-0002-5169-3631)
- Ravindran Kanesvaran (ORCID: https://orcid.org/0000-0002-2351-881X)
- Enrique Grande (ORCID: https://orcid.org/0000-0002-0134-4732)
- Javier Molina‐Cerrillo (ORCID: https://orcid.org/0000-0003-4616-0598)
- Mimma Rizzo (ORCID: https://orcid.org/0000-0001-7743-741X)
- Aristotelis Bamias (ORCID: https://orcid.org/0000-0002-5996-7262)
- Se Hoon Park (ORCID: https://orcid.org/0000-0001-5084-9326)
- Ray Manneh Kopp (ORCID: https://orcid.org/0000-0002-8106-9741)
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Yüksel Ürün (ORCID: https://orcid.org/0000-0002-9152-9887)
- Fernando Sabino Marques Monteiro (ORCID: https://orcid.org/0000-0002-6621-8251)
- Ugo De Giorgi (ORCID: https://orcid.org/0000-0001-7520-2908)
- Teresa Alonso‐Gordoa (ORCID: https://orcid.org/0000-0002-8966-7236)
- Renate Pichler (ORCID: https://orcid.org/0000-0001-5286-9048)
- Alessandro Rizzo (ORCID: https://orcid.org/0000-0003-1990-0490)
- Umberto Basso (ORCID: https://orcid.org/0000-0002-5075-2177)
- Jawaher Ansari (ORCID: https://orcid.org/0000-0001-5525-548X)
- Tomáš Büchler (ORCID: https://orcid.org/0000-0001-6667-994X)
- Hana Študentová (ORCID: https://orcid.org/0000-0003-2105-9258)
- Giuseppe Fornarini
- Pasquale Rescigno
Institutions
- University of Parma (IT)
- Royal Marsden NHS Foundation Trust (GB)
- University of Kentucky (US)
- Innsbruck Medical University (AT)
- Ankara University (TR)
- Universität Innsbruck (AT)
- National and Kapodistrian University of Athens (GR)
- Charles University (CZ)
- University Hospital Bonn (DE)
- Hospital Israelita Albert Einstein (BR)
- Samsung Medical Center (KR)
- Markey Cancer Center (US)
- Popular University of Cesar (CO)
- Tawam Hospital (AE)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University Hospital in Motol (CZ)
- Istituto Oncologico Veneto (IT)
- Azienda USL di Bologna (IT)
- Istituto Tumori Bari (IT)
- National Cancer Centre Singapore (SG)
- Ospedale Policlinico San Martino (IT)
- Hospital Sírio-Libanês (BR)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- MD Anderson Cancer Center Madrid (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Ospedale di Macerata
- University of Macerata (IT)
- Palacký University Olomouc (CZ)
- Newcastle University (GB)
- University of Bologna (IT)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1007/s00262-025-04019-x
- Citations
- 3
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56